Skip Navigation


Annals of Oncology Advance Access originally published online on June 20, 2006
Annals of Oncology 2006 17(8):1275-1282; doi:10.1093/annonc/mdl109
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/8/1275    most recent
mdl109v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tournilhac, O.
Right arrow Articles by Treon, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tournilhac, O.
Right arrow Articles by Treon, S. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling

O. Tournilhac1,2, D. D. Santos1,2, L. Xu1, J. Kutok2,3, Y.-T. Tai2,4, S. Le Gouill2,4, L. Catley2,4, Z. Hunter1,2, A. R. Branagan1,2, J. A. Boyce2,5, N. Munshi2,4, K. C. Anderson2,4 and S. P. Treon1,2,*

1 Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute; 2 Department of Medicine, Harvard Medical School; 3 Department of Pathology, Brigham and Women's Hospital; 4 Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA; 5 Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston MA, USA

* Correspondence to: Dr S. P. Treon, Bing Center for Waldenström's Macroglobulinemia, Dana Farber Cancer Institute, D1B07, 44 Binney Street, Boston MA 02115 USA. Tel: +1 (617) 632-2681; Fax: +1 (617) 632-4862; E-mail: steven_treon{at}dfci.harvard.edu

Bone marrow (BM) mast cells (MC) are commonly found in association with lymphoplasmacytic cells (LPC) in patients with Waldenström's macroglobulinemia (WM). We therefore sought to clarify the role of MC in WM. Co-culture of sublethally irradiated HMC-1 MC, KU812 basophilic cells, or autologous BM MC along with BM LPC from WM patients resulted in MC dose-dependent tumor colony formation and/or proliferation as assessed by 3H-thymidine uptake studies. Furthermore, by immunohistochemistry, multicolor flow cytometry and/or RT-PCR analysis, CD40 ligand (CD154), a potent inducer of B-cell expansion, was expressed on BM MC from 32 of 34 (94%), 11 of 13 (85%), and 7 of 9 (78%) patients, respectively. In contrast, MC from five healthy donors did not express CD154. By multicolor flow cytometry, CD154 was expressed on BM LPC from 35 of 38 (92%) patients and functionality was confirmed by CD154 and CD40 agonistic antibody stimulation, which induced proliferation, support survival and/or pERK phosphorylation of LPC. Moreover, MC induced expansion of LPC from 3 of 5 patients was blocked in a dose dependent manner by use of a CD154 blocking protein. These studies demonstrate that in WM, MC may support tumor cell expansion through constitutive CD154-CD40 signaling and therefore provide the framework for therapeutic targeting of MC and MC-WM cell interactions in WM.

Key words: mast cells, Waldenstrom's, macroglobulinemia, cd154, cd40, lymphoplasmacytic cells


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
X. Leleu, L. Xu, X. Jia, A. Sacco, M. Farag, Z. R. Hunter, A.-S. Moreau, H. T. Ngo, E. Hatjiharissi, A. W. Ho, et al.
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia
Blood, January 15, 2009; 113(3): 626 - 634.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. McEarchern, L. M. Smith, C. F. McDonagh, K. Klussman, K. A. Gordon, C. A. Morris-Tilden, S. Duniho, M. Ryan, T. E. Boursalian, P. J. Carter, et al.
Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
Clin. Cancer Res., December 1, 2008; 14(23): 7763 - 7772.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. W. Ho, E. Hatjiharissi, B. T. Ciccarelli, A. R. Branagan, Z. R. Hunter, X. Leleu, O. Tournilhac, L. Xu, K. O'Connor, R. J. Manning, et al.
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia
Blood, December 1, 2008; 112(12): 4683 - 4689.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X. Leleu, J. Eeckhoute, X. Jia, A. M. Roccaro, A.-S. Moreau, M. Farag, A. Sacco, H. T. Ngo, J. Runnels, M. R. Melhem, et al.
Targeting NF-{kappa}B in Waldenstrom macroglobulinemia
Blood, May 15, 2008; 111(10): 5068 - 5077.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Vijay and M. A. Gertz
Waldenstrom macroglobulinemia
Blood, June 15, 2007; 109(12): 5096 - 5103.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.